Basilea Pharmaceutica (OTCMKTS:BPMUF) Rating Increased to Hold at Zacks Research

Key Points

• Analysts at Zacks Research upgraded Basilea Pharmaceutica's stock rating to "hold" as of Wednesday.
• Basilea Pharmaceutica's shares opened at $67.75, with a one-year trading range between $47.50 and $67.75.
• The company develops biopharmaceutical products targeting oncology and anti-infectives, including the antifungal drug Cresemba.

Basilea Pharmaceutica (OTCMKTS:BPMUF - Get Free Report) was upgraded by analysts at Zacks Research to a "hold" rating in a research report issued on Wednesday,Zacks.com reports.

Basilea Pharmaceutica Stock Performance

Shares of OTCMKTS BPMUF opened at $67.75 on Wednesday. Basilea Pharmaceutica has a one year low of $47.50 and a one year high of $67.75. The company has a quick ratio of 4.16, a current ratio of 4.85 and a debt-to-equity ratio of 1.18. The business's fifty day moving average price is $66.72 and its 200-day moving average price is $57.80.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.